Betaine for the prevention and treatment of insulin resistance and fatty liver in a high-fat dietary model of insulin resistance in C57BL mice.
Study Goal
The researchers aimed to investigate how betaine improves hepatic insulin signaling in a dietary mouse model of insulin resistance and fatty liver, and its effects on insulin-resistant primary human hepatocytes.
Results Summary
Betaine supplementation reduced whole-body insulin resistance, improved glucose tolerance, and enhanced insulin signaling pathways in the liver of mice fed a high-fat diet. It also reversed insulin resistance in primary human hepatocytes by increasing insulin-stimulated phosphorylation of key proteins in the insulin signaling cascade.
Population
C57BL/6J mice and insulin-resistant primary human hepatocytes.
Effective Dosage
Not specified in the abstract.
Duration
14 weeks for the main experiment, with a subset receiving betaine for the final 4 weeks of an 18-week high-fat diet.
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
betaine | increase | hepatic insulin signaling | dietary mouse model of insulin resistance and fatty liver | - | improves | #1 |
HF diet | increase | body weight | C57BL 6J mice | - | were heavier | #2 |
HF diet | increase | hepatic steatosis | C57BL 6J mice | - | had more | #3 |
HF diet | neutral | glucose tolerance test (GTT) | C57BL 6J mice | - | abnormal | #4 |
HF diet | decrease | betaine content in liver and serum | C57BL 6J mice | 50% | was 50% lower | #5 |
betaine supplementation | increase | serum and liver betaine content | C57BL 6J mice fed HF diet | - | restored | #6 |
betaine treatment | decrease | whole body insulin resistance | C57BL 6J mice fed HF diet | - | reduced | #7 |
betaine treatment | increase | tyrosine phosphorylation of insulin receptor substrate-1 | C57BL 6J mice fed HF diet | - | increased | #8 |
betaine treatment | increase | phosphorylation (activation) of Akt | C57BL 6J mice fed HF diet | - | increased | #9 |
betaine treatment | increase | hepatic glycogen content | C57BL 6J mice fed HF diet | - | increased | #10 |
betaine | decrease | insulin resistance | insulin resistant primary human hepatocytes | - | reversed | #11 |
betaine | increase | insulin-stimulated tyrosine phosphorylation of IRS1 | insulin resistant primary human hepatocytes | - | increasing | #12 |
betaine | increase | insulin-stimulated tyrosine phosphorylation of Akt | insulin resistant primary human hepatocytes | - | increasing | #13 |
betaine supplementation | decrease | whole body insulin resistance | mouse model of insulin resistance and fatty liver | - | reduced | #14 |
betaine supplementation | increase | activation of insulin signaling pathways in the liver | mouse model of insulin resistance and fatty liver | - | increased | #15 |
betaine | decrease | liver injury | mouse model of insulin resistance and fatty liver | - | reduced | #16 |
betaine | decrease | insulin resistance | insulin resistant primary human hepatocytes | - | reversed | #17 |
betaine | increase | insulin-stimulated tyrosine phosphorylation of IRS1 | insulin resistant primary human hepatocytes | - | increasing | #18 |
betaine | increase | downstream proteins in the insulin signaling cascade | insulin resistant primary human hepatocytes | - | activation | #19 |
AIM: The aim was to investigate mechanisms by which betaine improves hepatic insulin signaling in a dietary mouse model of insulin resistance and fatty liver. METHODS: C57BL 6J mice were fed a standard diet (SF), a standard diet with betaine (SFB), a nutritionally complete high fat (HF) diet, or a high fat diet with betaine (HFB) for 14 weeks. In a separate experiment, mice were fed high fat diet for 18 weeks, half of whom received betaine for the final 4 weeks. Activation of insulin signaling in the liver was assessed by western blot. Insulin signaling was also assessed in insulin resistant primary human hepatocytes treated with betaine. RESULTS: As compared with SF, mice receiving HF diet were heavier, had more hepatic steatosis, and abnormal glucose tolerance test (GTT). Betaine content in liver and serum was 50% lower in HF than in SF; betaine supplementation restored serum and liver betaine content. Betaine treatment of HF reduced whole body insulin resistance as measured by GTT. Betaine treatment of HF increased tyrosine phosphorylation of insulin receptor substrate-1 and phosphorylation (activation) of Akt, and increased hepatic glycogen content. In vitro, betaine reversed insulin resistance in primary human hepatocytes by increasing insulin-stimulated tyrosine phosphorylation of IRS1 and of Akt. CONCLUSION: Betaine supplementation reduced whole body insulin resistance and increased activation of insulin signaling pathways in the liver in a mouse model of insulin resistance and fatty liver created by feeding a nutritionally complete high fat diet for 14 weeks. Betaine also reduced liver injury as assessed by ALT and by liver histology. In vitro, betaine reversed insulin resistance by increasing insulin-stimulated tyrosine phosphorylation of IRS1 and activation of downstream proteins in the insulin signaling cascade in insulin resistant primary human hepatocytes.